What is LivaNova's neuromodulation — 3t litigation provision?

LivaNova (LIVN) reported neuromodulation — 3t litigation provision of $0 in Q2 2026.

What does neuromodulation — 3t litigation provision mean?

Reflects the estimated financial liability accrued for legal proceedings specifically related to the 3T product line within the Neuromodulation segment. It serves as a measure of potential legal risk and financial impact from ongoing litigation.

LivaNova (LIVN) Neuromodulation — 3T litigation provision

Screener

Other segment segments

Cardiopulmonary

$11.32M+14,799%

Similar metrics at other companies

ABRStructured Business — Provisions for loss sharing (net of reversals)

$0—

ABRAgency Business — Provisions for loss sharing (net of reversals)

$4.54M+154%

MDTLitigation provision

$28.25M-64.4%

REXLitigation provision

$0—

EAT

EATLitigation provision

$0-100%

AMPYLitigation provision

$12K-97.0%

Other financials

Income statement

See full

Revenue$390.6M+10.8%

Gross profit$273.7M+14.5%

Operating income$49.5M-8.7%

Net income$108.6M+300%

EPS (diluted)$1.93+286%

Balance sheet

See full

Cash & equivalents$516.6M-13.0%

Total debt$348.5M-27.8%

Total equity$1.3B+18.0%

Total assets$2.6B+5.4%

Cash flow

See full

Operating cash flow$66.6M+5.8%

CapEx$31.6M+108%

Free cash flow$35.0M-26.7%

Valuation

See full

Market cap$4.17B+61.5%

Enterprise value$4.01B+61.9%

P/E22.6×-67.9×

P/S2.8×+0.9×

Profitability

See full

Gross margin68.1%+0.1pp

Operating margin12.7%-0.7pp

Net margin-16.1%-18.0pp

FCF margin10.1%-2.3pp

Returns & leverage

See full

Return on equity-17.6%-19.5pp

Debt / equity0.3×-0.2×

Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:LossContingencyLossInPeriod.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 2:23 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001639691-26-000090

Line item	Cardiopulmonary / Three Months Ended June 30, 2026	Cardiopulmonary / Three Months Ended June 30, 2025	Neuromodulation / Three Months Ended June 30, 2026	Neuromodulation / Three Months Ended June 30, 2025
Cost of sales	97,265	95,465	14,455	14,769
Selling, general, and administrative	66,465	56,012	56,568	51,097
Research and development	18,376	16,465	34,987	29,784
3T litigation provision	11,318	(77)	—	—
	$28,152	$31,407	$60,935	$56,020
	Cardiopulmonary		Neuromodulation
	Six Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's neuromodulation — 3t litigation provision?: LivaNova (LIVN) reported neuromodulation — 3t litigation provision of $0 in Q2 2026.
What does neuromodulation — 3t litigation provision mean?: Reflects the estimated financial liability accrued for legal proceedings specifically related to the 3T product line within the Neuromodulation segment. It serves as a measure of potential legal risk and financial impact from ongoing litigation.